Topamax (topiramate), when taken by pregnant women, greatly increases the risk that their babies will develop birth defects, like cleft lips and cleft palates, the U.S. Food and Drug Administration warned recently. Alternative medications have lower risks of causing birth defects, and women treated with Topamax during pregnancy whose children were born with birth defects are increasingly filing suit to be compensated. Johnson Law Group is evaluating and accepting Topamax cases now.
“More than 4.3 million patients filled Topamax prescriptions in the U.S. in the last four years,” said Attorney Nick Johnson, founder of Johnson Law Group. “That includes a significant number of women who may never have known how dangerous Topamax could be for their developing infants. Those women and children deserve justice.”
The FDA has said, “…topiramate is being placed in Pregnancy Category D. Pregnancy Category D means there is positive evidence of human fetal risk … an increased risk for oral clefts … based on human data.” Previously the drug was listed as a Category C drug, which recognizes that animal studies “suggested potential fetal risk.”
Topamax (topiramate) is an anticonvulsant medication used, sometimes in conjunction with other medications, to treat epilepsy patients with certain types of seizures, and sometimes to prevent migraine headaches.
If you would like to file a complaint, or simply need more information about the birth defects caused by Topamax, call 1-800-217-9891 or visit: http://pharmaceuticals.johnsonlawgroup.com/topamax-and-birth-defects.
Johnson Law Group is comprised of experienced personal injury attorneys. The firm offers legal and medical professional investigative skills, expert witnesses, cutting-edge technology, and state-of-the-art techniques for maximum recovery. Nick Johnson leads the Johnson Law Group. He graduated from Duke University and the University of Houston Law Center. Mr. Johnson practices in all areas of personal injury law, with a primary focus on pharmaceutical and asbestos related lung cancer cases.
Related Coverage
- CVS Caremark: Dispense as Written Prescriptions Will Add $7.7 Billion to Annual Health Care Costs
- LUNGevity Foundation Praises Recent FDA Approval of New Lung Cancer Treatment Drug XALKORI® (crizotinib)
For more reporting on this topic, see our Prescription Drugs and Pharmacy news hub.